vs
M&T Bank（MTB）与梯瓦制药（TEVA）财务数据对比。点击上方公司名可切换其他公司
梯瓦制药的季度营收约是M&T Bank的1.9倍（$4.7B vs $2.5B），M&T Bank净利率更高（30.7% vs 10.2%，领先20.5%），梯瓦制药同比增速更快（11.4% vs 3.8%），过去两年梯瓦制药的营收复合增速更高（11.1% vs 4.6%）
M&T银行是总部位于美国纽约州布法罗的银行控股企业，业务覆盖美国东部从缅因州到弗吉尼亚州的12个州及华盛顿特区，运营超过950家线下网点。其控股主体1998年5月前名为第一帝国州公司，之后更为现名。
梯瓦制药工业有限公司是以色列跨国制药企业，核心业务聚焦仿制药研发生产，同时布局品牌药、药用活性成分（API）业务，也小范围开展合同生产服务及对外授权合作相关业务。
MTB vs TEVA — 直观对比
营收规模更大
TEVA
是对方的1.9倍
$2.5B
营收增速更快
TEVA
高出7.6%
3.8%
净利率更高
MTB
高出20.5%
10.2%
两年增速更快
TEVA
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.5B | $4.7B |
| 净利润 | $759.0M | $481.0M |
| 毛利率 | — | 56.4% |
| 营业利润率 | 39.2% | 6.4% |
| 净利率 | 30.7% | 10.2% |
| 营收同比 | 3.8% | 11.4% |
| 净利润同比 | 11.5% | 321.7% |
| 每股收益（稀释后） | $4.62 | $0.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MTBTEVA
| Q4 25 | $2.5B | $4.7B | ||
| Q3 25 | $2.5B | $4.5B | ||
| Q2 25 | $2.4B | $4.2B | ||
| Q1 25 | $2.3B | $3.9B | ||
| Q4 24 | $2.4B | $4.2B | ||
| Q3 24 | $2.3B | $4.3B | ||
| Q2 24 | $2.3B | $4.2B | ||
| Q1 24 | $2.3B | $3.8B |
净利润MTBTEVA
| Q4 25 | $759.0M | $481.0M | ||
| Q3 25 | $792.0M | $433.0M | ||
| Q2 25 | $716.0M | $282.0M | ||
| Q1 25 | $584.0M | $214.0M | ||
| Q4 24 | $681.0M | $-217.0M | ||
| Q3 24 | $721.0M | $-437.0M | ||
| Q2 24 | $655.0M | $-846.0M | ||
| Q1 24 | $531.0M | $-139.0M |
毛利率MTBTEVA
| Q4 25 | — | 56.4% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | — | 50.3% | ||
| Q1 25 | — | 48.2% | ||
| Q4 24 | — | 50.2% | ||
| Q3 24 | — | 49.6% | ||
| Q2 24 | — | 48.6% | ||
| Q1 24 | — | 46.4% |
营业利润率MTBTEVA
| Q4 25 | 39.2% | 6.4% | ||
| Q3 25 | 40.8% | 19.7% | ||
| Q2 25 | 39.0% | 10.9% | ||
| Q1 25 | 33.0% | 13.3% | ||
| Q4 24 | 37.0% | -0.7% | ||
| Q3 24 | 39.0% | -1.2% | ||
| Q2 24 | 37.1% | -0.1% | ||
| Q1 24 | 29.4% | -5.7% |
净利率MTBTEVA
| Q4 25 | 30.7% | 10.2% | ||
| Q3 25 | 31.5% | 9.7% | ||
| Q2 25 | 29.9% | 6.8% | ||
| Q1 25 | 25.3% | 5.5% | ||
| Q4 24 | 28.6% | -5.1% | ||
| Q3 24 | 30.9% | -10.1% | ||
| Q2 24 | 28.5% | -20.3% | ||
| Q1 24 | 23.5% | -3.6% |
每股收益（稀释后）MTBTEVA
| Q4 25 | $4.62 | $0.42 | ||
| Q3 25 | $4.82 | $0.37 | ||
| Q2 25 | $4.24 | $0.24 | ||
| Q1 25 | $3.32 | $0.18 | ||
| Q4 24 | $3.87 | $-0.19 | ||
| Q3 24 | $4.02 | $-0.39 | ||
| Q2 24 | $3.73 | $-0.75 | ||
| Q1 24 | $3.02 | $-0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $3.6B |
| 总债务越低越好 | $10.9B | — |
| 股东权益账面价值 | $29.2B | $7.9B |
| 总资产 | $213.5B | $40.7B |
| 负债/权益比越低杠杆越低 | 0.37× | — |
8季度趋势，按日历期对齐
现金及短期投资MTBTEVA
| Q4 25 | — | $3.6B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.2B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | — | $3.3B | ||
| Q2 24 | — | $2.3B | ||
| Q1 24 | — | $3.0B |
总债务MTBTEVA
| Q4 25 | $10.9B | — | ||
| Q3 25 | $12.9B | — | ||
| Q2 25 | $12.4B | — | ||
| Q1 25 | $10.5B | — | ||
| Q4 24 | $12.6B | — | ||
| Q3 24 | $11.6B | — | ||
| Q2 24 | $11.3B | — | ||
| Q1 24 | $11.4B | — |
股东权益MTBTEVA
| Q4 25 | $29.2B | $7.9B | ||
| Q3 25 | $28.7B | $7.3B | ||
| Q2 25 | $28.5B | $6.8B | ||
| Q1 25 | $29.0B | $6.3B | ||
| Q4 24 | $29.0B | $5.4B | ||
| Q3 24 | $28.9B | $6.1B | ||
| Q2 24 | $28.4B | $6.4B | ||
| Q1 24 | $27.2B | $7.3B |
总资产MTBTEVA
| Q4 25 | $213.5B | $40.7B | ||
| Q3 25 | $211.3B | $39.9B | ||
| Q2 25 | $211.6B | $40.1B | ||
| Q1 25 | $210.3B | $38.4B | ||
| Q4 24 | $208.1B | $39.3B | ||
| Q3 24 | $211.8B | $41.8B | ||
| Q2 24 | $208.9B | $41.3B | ||
| Q1 24 | $215.1B | $42.8B |
负债/权益比MTBTEVA
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.36× | — | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 0.40× | — | ||
| Q2 24 | 0.40× | — | ||
| Q1 24 | 0.42× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.0B | $1.2B |
| 自由现金流经营现金流 - 资本支出 | — | $1.0B |
| 自由现金流率自由现金流/营收 | — | 21.6% |
| 资本支出强度资本支出/营收 | — | 3.0% |
| 现金转化率经营现金流/净利润 | 3.96× | 2.41× |
| 过去12个月自由现金流最近4个季度 | — | $1.1B |
8季度趋势，按日历期对齐
经营现金流MTBTEVA
| Q4 25 | $3.0B | $1.2B | ||
| Q3 25 | $1.0B | $369.0M | ||
| Q2 25 | $844.0M | $227.0M | ||
| Q1 25 | $635.0M | $-105.0M | ||
| Q4 24 | $3.6B | $575.0M | ||
| Q3 24 | $-28.0M | $693.0M | ||
| Q2 24 | $1.4B | $103.0M | ||
| Q1 24 | $608.0M | $-124.0M |
自由现金流MTBTEVA
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $233.0M | ||
| Q2 25 | — | $131.0M | ||
| Q1 25 | — | $-232.0M | ||
| Q4 24 | — | $446.0M | ||
| Q3 24 | — | $545.0M | ||
| Q2 24 | — | $6.0M | ||
| Q1 24 | — | $-248.0M |
自由现金流率MTBTEVA
| Q4 25 | — | 21.6% | ||
| Q3 25 | — | 5.2% | ||
| Q2 25 | — | 3.1% | ||
| Q1 25 | — | -6.0% | ||
| Q4 24 | — | 10.5% | ||
| Q3 24 | — | 12.6% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | -6.5% |
资本支出强度MTBTEVA
| Q4 25 | — | 3.0% | ||
| Q3 25 | — | 3.0% | ||
| Q2 25 | — | 2.3% | ||
| Q1 25 | — | 3.3% | ||
| Q4 24 | — | 3.1% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 2.3% | ||
| Q1 24 | — | 3.2% |
现金转化率MTBTEVA
| Q4 25 | 3.96× | 2.41× | ||
| Q3 25 | 1.26× | 0.85× | ||
| Q2 25 | 1.18× | 0.80× | ||
| Q1 25 | 1.09× | -0.49× | ||
| Q4 24 | 5.30× | — | ||
| Q3 24 | -0.04× | — | ||
| Q2 24 | 2.07× | — | ||
| Q1 24 | 1.15× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MTB
暂无分部数据
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
